Background: Side effects of antidepressants are usually underreported in clinical trials and large scale naturalistic studies are restricted to six months of use. We examined the prevalence and nature of patient-perceived side effects and their determinants during longterm antidepressant use in a naturalistic setting.
INTRODUCTION
Antidepressant use is associated with a variety of side effects (SEs). In clinical trials their prevalence is up to 27%. 1 SEs interfere with optimal treatment dosages and may be the cause of medication non-adherence and discontinuation. 2 Although SEs should be known before an antidepressant is introduced in daily practice, SE assessment in clinical trials concerning mental health is inadequate, particularly with respect to long-term effects. 3 A large scale meta-analysis of 143 clinical trials on antidepressants showed that structured and systematic SE assessment strategies were used in only 21% of these trials. 4 Moreover, a systematic review on 115 studies revealed that only a few trials used an objective side effect rating scale whereas adverse events were rarely pre-specified and defined. 5 In clinical trials often only short-term severe SEs are reported. This lack of adequate SE data is hindering the evaluation of antidepressant risk-benefit ratios. 3 Although participants of antidepressant clinical trials represent only a small highly selected minority of depressed patients in clinical practice, trial results on efficacy can be generalized to the general population. 6;7 Clinical trials have revealed differences in SE profiles among different types of antidepressants. 1;5;8-10 However, it is not clear whether there is similarity between SEs reported in clinical trials and those occurring in daily practice. 6;7 Prescription Event Monitoring has provided naturalistic SE data in a primary care setting of short-term (up to 6 months) antidepressant use [11] [12] [13] , but antidepressant-induced SE data in a long-term naturalistic setting is lacking.
Little is known about the persistence of patient-perceived SEs during long-term antidepressant use. In a large short-term study comparing citalopram and nortriptyline most SEs, which were assessed on a weekly basis, decreased over a 12 week study period. 14 The clinical notion that SEs wear off during prolonged use over years is not substantiated with data. The mean incidence of headache and nausea in 27 antidepressant continuationand maintenance-phase studies was 16% and 7%, respectively. Compared to acute phase studies, the relative incidence of these events was only slightly lower. 15 Finally, reports of long-term clinical trials also seldomly provide differentiation between SE prevalence at the beginning of the trial and SE prevalence after 6 to 24 months of continued treatment. 16;17 Patient-, disease-and treatment-related factors like age [18] [19] [20] , depression severity 14;21 and type and dose of antidepressant 1;9;10 influence the occurrence and severity of SEs in clinical trials. Because of unknown external validity of SE data from clinical trials to long-term daily use and the lack of systematic SE data comparing different antidepressants over an extended time course, it is important to study antidepressant-induced SEs during long-term use in a naturalistic setting. We therefore examined the prevalence, nature and determinants of SEs during long-term use of different types of antidepressants in a naturalistic setting.
METHODS

Study sample
All subjects participating in the present study came from the Netherlands Study of Depression and Anxiety (NESDA), an ongoing longitudinal cohort study conducted among 2,981 adult subjects (18-65 years) to examine (predictors of ) the long-term course of depression and anxiety disorders. The rationales, methods and recruitment strategy have been described elsewhere. 22 The NESDA sample consists of 652 persons without depression or anxiety disorders and 2,329 with a (remitted or current) diagnosis of a depressive and/or anxiety disorder. In order to represent various settings and stages of psychopathology, depressed or anxious subjects were recruited at three different locations in the Netherlands in different settings: community, primary care, and specialized mental health care. Community-based subjects were previously identified in two population-based studies (Nemesis and Ariadne). Primary care subjects were identified through a 2-stage screening procedure (involving the K10 questionnaire 23;24 and the CIDI-SF [Composite International Diagnostic Interview, Short Form] telephone interview) conducted among patients of 65 general practitioners. Mental health care patients were recruited when newly admitted to one of the 17 participating mental health organizations. Subjects with clinically overt psychotic disorder, obsessive compulsive disorder, bipolar disorder, or severe addiction disorder were excluded. The study protocol was approved centrally by the Ethical Review Board of the VU University Medical Center and subsequently by local review boards of each participating center. All subjects signed an informed consent at baseline assessment.
NESDA subjects were enrolled between September 2004 and February 2007. One-year follow-up data were acquired by means of a written questionnaire (n=2,445) and the twoyear follow up data were obtained by means of a face to face interview (n=2,596).
All subjects who reported to use antidepressants or did so in the year preceding the first (1-year) and/or second (2-year) follow-up, were included in the study sample (n=907). If subjects reported on the same antidepressant at both assessments, we have used the first assessment and excluded the second assessment in order not to bias the prevalence of side effects. Subjects using two antidepressants at the same time (n=61) were excluded in order to avoid attribution of SEs to the wrong antidepressant. 81 Subjects reported two different episodes of single antidepressant use. Therefore, our study sample consisted of 927 cases of antidepressant use within 846 subjects. 625 Cases originated from the one-year follow-up data and 302 cases from the two-year follow-up. 76% of the cases (n=701) reported SEs on current use, the others reported SEs while not currently on medication anymore. All data was obtained at the time of the SE assessment.
Medication use
Current medication use including name, dose end daily amount of both psychotropic and non-psychotropic medication, was inventoried with the aid of the subjects' medication boxes. Medication use was checked whether the information provided was pharmaceutically possible. Duration of use of the antidepressant on which SEs were reported, was noted in months. We classified medications by using the World Health Organization Anatomical Therapeutic Chemical (ATC) system. 25 We distinguished selective serotonin re-uptake inhibitors (SSRIs, ATC code N06AB), tricyclic antidepressants (TCAs, ATC code N06AA), venlafaxine (ATC code N06AX16), mirtazapine (ATC code N06AX11) and other antidepressants (including monoamine oxidase inhibitors, non-selective N06AF and antidepressants classified as N06AX, excluding N06AX11 and N06AX16). For all antidepressants a derived daily dose was calculated by dividing the subject's daily dose used by the defined daily dose (DDD) recommended by the WHO. 25 Benzodiazepine use was determined by selecting ATC codes N03AE, N05BA, N05CD and N05CF.
Side effects
SEs were collected for every psychotropic drug, including alternative medicines like St John's wort, the subject used on a daily basis and for all psychotropic medication used in the last year. A short 12-question self-report Antidepressant Side Effect Checklist (ASEC-12) was constructed. Recently, the self-report ASEC-21 was validated 14 against the UKU Side Effect Rating Scale, a semistructured interview by a health professional. 26 The ASEC-12
shortlist specifically asks for the presence of patient-perceived SEs, related to antidepressant therapy: insomnia, sleepiness during the day, restlessness, muscle spasms/twitching, dry mouth, profuse sweating, sexual disorders, nausea, constipation, diarrhea, weight gain and dizziness. We did not define a specific time period in which the SEs should have occurred and expect to measure current side effects or side effects that have occurred recently.
Psychiatric status
The presence of depressive and anxiety disorders in the preceding two years was assessed using the CIDI psychiatric interview. The presence or absence of a major depressive disorder, minor depressive disorder, dysthymia, panic disorder (with or without agoraphobia), social phobia or generalized anxiety disorder was also assessed. The CIDI establishes diagnoses according to DSM-IV criteria 27 and has shown high inter-rater and test-retest reliability and high validity for depressive disorders. 28 The severity of depression was evaluated using the 30-item Inventory of Depressive Symptoms self-report version (IDS-SR), which also includes various anxiety items. 29 Alcohol dependence and alcohol abuse was assessed with the CIDI interview.
Statistical analyses
SE parameters were compared in the four groups of antidepressants, being SSRI, TCA, venlafaxine and mirtazapine (n=884), excluding 'St John's wort' and 'other antidepressants' . The numbers of SEs per case were divided in three categories: 'no SEs' , 'one or two SEs' and 'three or more SEs' . Overall p-values were calculated using χ 2 -statistics for the categories of the number of SEs and the presence of specific SEs. The four groups of antidepressants were individually compared with univariate analyses using χ 2 -statistics. P-value cut-offs of 0.05 were considered as significant.
In a multivariate analysis we included subject-related factors (gender, age, years of education), disease related factors (depression symptom severity, number of psychiatric diagnoses and benzodiazepine use) and antidepressant-related factors (type of antidepressant, dose and duration). The numbers of SEs, divided in the three categories, were analyzed using multinomial logistic regression analysis. Multivariate logistic regression analyses were used for the presence of SEs with a prevalence of 10% or higher. Data were analyzed using SPSS 15.0.
RESULTS
Demographics and basic characteristics of the 846 subjects are presented in Table  1 . Their mean age was 43.0 years and 67 % was female. 38% Of the 927 cases had a comorbid depression and anxiety disorder and 31% used a benzodiazepine. SSRI use (63%) mainly concerned paroxetine, fluoxetine, citalopram and escitalopram. TCA use included amitriptyline, nortriptyline and clomipramine. In 2.6% of the cases St John's wort was used.
In 64% of cases of antidepressant use, on average 2.9 SEs were reported. Absence of SEs was more common with SSRI use, as compared to venlafaxine use (p=0.03) and, although not significantly, compared with TCA use (p=0.10)( Table 2) . No SEs were reported for alternative treatment with St John's wort.
The average prevalence of specific SEs ranged from 6 to 25%. As compared to SSRIs, TCAs caused more typical anticholinergic SEs like constipation and dry mouth. As compared to SSRIs, the use of venlafaxine was associated with more muscle spasms/twitching, profuse sweating, sexual dysfunction and dizziness. Mirtazapine was associated with more sleepiness during the day and but less constipation and sexual dysfunction. In this univariate analysis we did not find a clear positive association between mirtazapine use and weight gain as compared to SSRIs. 
Determinants of SEs in multivariate analyses,
SE reporting was associated with depression severity and additional psychiatric diagnoses, TCA use and higher dosages. SE reporting was negatively associated with age, concurrent use of benzodiazepines and prolonged antidepressant use (see Table 3 ). Analyses of comparing 'one or two SEs' and 'three or more SEs' versus reporting 'no SEs' show consistency in the directions of these associations. Except for 'years of education' , the analysis of 'three or more SEs' showed stronger associations. In contrast with the univariate analysis, the use of TCAs was independently associated with more reporting 'one or two SEs' and 'three or more SEs' as compared to SSRIs. Venlafaxine and mirtazapine did not show this difference.
Although females did not report more SEs, female gender was associated with more constipation and weight gain and with less sexual dysfunction (see Table 4 ). Higher age was associated with less sleepiness during the day, less profuse sweating and less dizziness. Depression severity was associated with dizziness and anticholinergic SEs like constipation and dry mouth. TCAs were associated with more anticholinergic SEs compared with SSRIs. Venlafaxine only differed from SSRIs in its association with more profuse sweating. Concurrent benzodiazepine use was associated with less profuse sweating. Compared with SSRIs, mirtazapine showed less sexual dysfunction and more weight gain. The dose of the antidepressant was associated with increased odds for most specific SEs with odds ratios between 1.1 and 1.5.
DISCUSSION
This naturalistic study shows that patient-perceived SEs are common and persist during long-term antidepressant use in a large cohort of patients with depression and/or anxiety disorders. Our structured inventory of 12 common antidepressant SEs confirms the known differences in SE profiles among different types of antidepressants. However, it also shows venlafaxine to be associated with more profuse sweating compared with SSRIs. The number of reported SEs is higher at younger patient age, higher depression severity, more psychiatric diagnoses, higher antidepressant dose and shorter duration of use. Weight gain is associated with female gender and longer duration of use. Other specific SEs are associated with antidepressant dose and/or depression severity.
Our multivariate model (table 3) indicates that SEs are more common with TCAs as compared to SSRI, whereas this difference is not shown for venlafaxine and mirtazapine. This is in line with a meta-analysis of many short-term clinical trials, where TCAs had inferior tolerability compared with SSRIs. 8 A meta-analysis of clinical trial data shows venlafaxine to be more efficacious and have more SEs compared with SSRIs. 30 Short-term prescription event monitoring in primary care setting shows no major differences in SE reporting. 13 In long-term use we now find no difference in the number of reported SEs between SSRI and venlafaxine. This is shown in a multivariate model, that includes the dose of the antidepressant. Hereby, we provide an intrinsic comparison between the types of antidepressants independent of the dose. This could provide an explanation for the differences found in clinical trials, where high dosages of venlafaxine were used to provide higher efficacy at the cost of decreased tolerability as compared to SSRIs. 30 In multivariate analysis, mirtazapine showed less sexual dysfunction and more weight gain when compared with SSRIs in long-term use. These are two important features of mirtazapine, which have previously been demonstrated in shortterm studies. 9 In several long-term studies of Hypericum extracts, 16;31 placebo level SEs are reported. We did not have a single report of SEs on the use of St John's wort preparations, but this could be due to the fact that these preparations were not licensed at the time of data collection and detailed information on preparation strengths and dosages used was not available. These alternative treatments were not prescribed by medical doctors and were taken on the patient's own instigation, possibly resulting in easy discontinuation of treatment in case of side effects. In addition, the number of John's wort users in this sample was very small, limiting the interpretation of our findings regarding this sample. In a short-term study, detailed information on the time course of SEs of escitalopram and nortriptyline has been published.
14 Prevalence of drowsiness, headache, nausea and orthostatic dizziness dropped, whereas other SEs, particularly anticholinergic SEs and sexual dysfunction, persisted over the 12-week treatment course. In the present study we find slightly lower SE reporting with prolonged antidepressant use, while no associations are detected between specific SEs and prolonged use. During long-term antidepressant use, all specific SEs seem to persist.
In univariate analyses, anticholinergic SEs, like dry mouth and constipation, were reported more often with TCA use, compared with all other types of antidepressants. In multivariate analyses, the dose of the antidepressant was associated with increased odds on overall SEs and specific SEs. These findings are well known from clinical trials and are therefore important markers of the validity of our findings in a naturalistic setting.
Elderly people generally are more sensitive to the toxic effects of psychotropic medication. 19 In this patient group particular attention goes to the risk of adverse outcomes, like falls, fractures, upper gastrointestinal bleeding, epilepsy/seizures and hyponatremia. 18;32 However, looking at patient perceived SEs, in the present study SE reporting declines with age. Such a negative association with age is also found for several specific SEs, like sleepiness during the day, profuse sweating and dizziness. These results are in line with those obtained for the SSRI citalopram. For a range of specific SEs including headache, nausea, diarrhoea and sweating, younger people of 18-64 years of age reported more SEs than patients older than 65 years. 33 For serotonergic SEs, like nausea, diarrhoea and sweating, this effect might be caused by the age-related reduction of sensitivity of the serotonergic system. 34 However, a cohort study on short-term SSRI use involving more than 40.000 users, found no differences in SEs between the elderly (> 70 yrs) and younger patients (< 70 yrs). 11 The present results on patient-perceived SEs during long-term use contribute to the on-going debate on the association between age and SEs.
Both depression severity and an increased number of psychiatric disorders are associated with increased overall SE reporting. Depression severity is also positively associated with specific SEs, like dry mouth, constipation and dizziness. The association of depression severity and SE reporting has been described previously in a short-term antidepressant trial 14 and for long-term lithium use. 21 Uher et al. showed that this association was not caused by confounding in the assessment of SEs and depression severity. A mechanism for perceiving and reporting more SEs by more severely disease-affected patients could be their increased sensitivity and attention to physical discomfort as has been observed with pain perception in depression. 35 A recent meta-analysis showed large differences in weight gain between individuals as the result of treatment with various antidepressants. 36 In the present study female gender and prolonged antidepressant use are found to be associated with weight gain. However, this finding could be biased by the fact that part of the women might be more dissatisfied with their body weight and shape when compared to men 37 and the natural tendency for people to get heavier over the years. Nevertheless, body weight increase as the result of antidepressant use should be monitored carefully as it is an important risk factor for the metabolic syndrome.
Profuse sweating can be very distressing and may cause impairment in social and occupational functioning. In the present study substantially more patients using venlafaxine experienced profuse sweating as compared with SSRI users. In a recent long-term efficacy study, sweating was reported in 16% of the patients after 8 to 20 months of venlafaxine use at average dosages of 225 mg a day, and 10% of the patients on fluoxetine at average dosages of 50 mg a day did. 17 In our study, when specifically asked, profuse sweating was experienced in 32% of venlafaxine users and 20% of SSRI users. Due to our large study population this difference was statically significant both in univariate as well as multivariate analyse. High antidepressant dosages were also associated with increased odds for profuse sweating. This finding supports cases that SSRI-induced sweating resolved after dose reduction. 38 In contrast with sweating as a side effect, low doses venlafaxine and paroxetine are effective in preventing sweating as a part of the treatment for vasomotor symptoms in menopausal women. 39 The concurrent use of benzodiazepines was associated with less profuse sweating.
In a small placebo controlled trial on hyperhydrosis in patients with a social anxiety disorder clonazepam was as efficacious as fluoxetine. 40 These data suggest that benzodiazepines may be helpful when hyperhydrosis triggered by psychosocial stressors emerges as SE in patients treated with antidepressants.
A strength of the present study is the use of the NESDA cohort which provides a large dataset on both clinical features of depression and anxiety including indicators of the CIDI diagnosis and severity of symptoms through validated scales. NESDA incorporates large groups of severely affected patients both with depression and anxiety disorders. These groups are often under-represented in large population-based surveys and in clinical trials. We used the same self-report structured SE ASEC 12 shortlist for all types of antidepressants. The assessment of patient-perceived SEs by self-report has recently been validated against the psychiatrist rated UKU Side effect Rating Scale. 14 A few limitations need to be discussed.
Because we did not define a specific time period in which the SEs should have occurred, severe side effects from earlier times could be measured due to re-call bias. All participants of the present study were familiar with the medication they used and were likely informed on possible SEs, which is known to influence SEs reporting. 4 Moreover, due to the naturalistic setting, associations between SEs and type of antidepressant, dose and duration may have been weakened by routine clinical measures like lowering of dosages, switching and discontinuation of the antidepressant. We did not provide data on preceding antidepressant use. In case of short duration of antidepressant use, preceding use with an antidepressant from the same therapeutic class could, in theory, slightly lower the prevalence of classspecific side effects due to tolerance.
In conclusion, the present large naturalistic cohort study shows that during long-term use SEs to antidepressants are common. Known differences in SE profiles between various types of antidepressants observed in short-term studies are confirmed. In addition, as compared to SSRI treatment, venlafaxine was associated with more profuse sweating. Weight gain is associated with female gender and longer duration of use. Other specific SEs are associated with antidepressant dose and depression severity. Although prolonged antidepressant use is weakly associated with less SE reporting, clinicians should be aware that antidepressantinduced SEs are persistent. SEs should, therefore, be incorporated in the evaluation of ongoing antidepressant therapy.
